Basilea Pharmaceutica Presents New Data at IDWeek 2026
News related to:Basilea Pharmaceutica Ltd · 1 min read
Basilea Pharmaceutica Ltd, a biopharmaceutical company founded in 2000 and headquartered in Switzerland, announced the presentation of new data for its antifungal and antibiotic drugs at IDWeek 2026, taking place from October 21 to 24 in Washington D.C., USA. The company's focus on pediatric data from the fosmanogepix Expanded Access Program and the activity of its active moiety, manogepix, against Candida auris isolates, highlights the breadth of its commitment to addressing unmet medical needs in the treatment of serious infections.
The fosmanogepix development program, funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033, is a testament to the company's dedication to innovation. Similarly, Basilea's ceftobiprole phase 3 program, funded in part with federal funds from the same sources, under contract number HHSO100201600002C, has been instrumental in advancing the treatment of bacterial infections.
In a separate development, Basilea reported a significant financial performance for the period ending September 14, 2026. The company's total revenue increased by 14% to CHF 119 million, while operating profit surged by 32% to CHF 32 million, and net profit rose by 77% to CHF 28 million. These figures reflect the company's progress and the success of its product portfolio.
The company's achievements are not limited to financial performance. The fosmanogepix phase 3 program is on track for data readout, which is expected to provide crucial insights into the efficacy and safety of the drug. This progress is part of Basilea's ongoing efforts to develop innovative treatments for severe bacterial and fungal infections, addressing the growing need for effective therapies in the medical community.
In summary, Basilea Pharmaceutica Ltd's presentations at IDWeek 2026 and its financial performance underscore the company's commitment to advancing the treatment of serious infections. The company's continued investment in research and development, coupled with its financial success, positions it as a leader in the biopharmaceutical industry.